Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,104.34 -5.60 (-0.50%)

Official Closing Price Updated: 4:10 PM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗

November 18, 2025

The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow.

Via Investor's Business Daily

Topics Government

Oprah Winfrey-Backed Wellness Stock Stumbles As GLP-1 Boom Reshapes Consumer Habits: Growth Score Plummets ↗

November 18, 2025

Prominent weight-loss and wellness company, WW International Inc. (NASDAQ: WW), backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this...

Via Benzinga

Topics Bankruptcy

1 Profitable Stock with Exciting Potential and 2 Facing Challenges

November 17, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3

November 17, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch

November 17, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Pfizer (NYSE:PFE)

November 17, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy? ↗

November 17, 2025

Pfizer's weight management pipeline just got a boost.

Via The Motley Fool

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗

November 17, 2025

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Via Benzinga

Topics Artificial Intelligence

Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗

November 17, 2025

With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.

Via Benzinga

Topics ETFs

Consumer Brands Shake Things Up...With Mergers ↗

November 17, 2025

2025 has been quite the year for consumer brands, but not in a good way. The industry has underperformed for the past three years and many of the world's largest consumer brand companies are resorting...

Via The Motley Fool

Topics Artificial Intelligence Economy

Nvidia and 19 Other Stocks Now Make Up 50% of the S&P 500. Here's What It Means for Your Investment Portfolio. ↗

November 17, 2025

Buying the S&P 500 takes the belief that today's leading companies deserve their lofty valuations.

Via The Motley Fool

Topics Stocks

Market Grapples with Valuation Fears Amidst Accelerating Sector Rotation

November 17, 2025

As November 2025 unfolds, the global financial markets find themselves at a critical juncture, characterized by a palpable sense of unease over elevated valuations in specific sectors and a pronounced...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration ↗

November 17, 2025

Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.

Via Investor's Business Daily

Topics Government

White House Economic Advisor Kevin Hassett Says India Trade Deal Talks Got ‘Pretty Complicated’, But Remains Hopeful: Report ↗

November 17, 2025

In an interview with CNBC, Hassett remained optimistic about striking an agreement with India, but added that there are a lot of different variables in the India-U.S. relationship.

Via Stocktwits

Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound ↗

November 17, 2025

The Danish drugmaker has announced that this offer is applicable to cash-paying patients looking to purchase introductory doses of Wegovy and Ozempic.

Via Stocktwits

Topics Artificial Intelligence

This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000? ↗

November 17, 2025

Healthcare stocks have far outperformed the broader market over the past month.

Via The Motley Fool

Topics ETFs Government World Trade

2 Mooning Stocks to Keep an Eye On and 1 We Ignore

November 16, 2025

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Via StockStory

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? ↗

November 16, 2025

Investors will be watching what Trump makes happen.

Via The Motley Fool

Topics Government

Prediction: This Will Be Wall Street's Next Trillion-Dollar Stock ↗

November 16, 2025

Drugs for weight loss and diabetes are taking Eli Lilly to new heights.

Via The Motley Fool

Maplebear, Tower Semiconductor, And Eli Lilly Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 10-Nov. 14): Are the Others in Your Portfolio? ↗

November 16, 2025

Ten large-cap standouts—including Maplebear, Tower Semiconductor, Eli Lilly, On Holding, Albemarle, and key gold/silver miners—rallied last week on strong earnings, upbeat guidance, analyst upgrades,...

Via Benzinga

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗

November 15, 2025

A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.

Via Benzinga

Topics ETFs

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

Government Reopens, AI Stocks Slide On Supply Crunch Fears: This Week In Markets ↗

November 14, 2025

Markets digest U.S. government reopening, hawkish Fed outlook, and AI sell-off as CoreWeave crashes 25%.

Via Benzinga

Topics Artificial Intelligence Economy

Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗

November 14, 2025

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

Via Benzinga

Topics Artificial Intelligence

Novo Nordisk Brings Back Former CEO To Lead Board ↗

November 14, 2025

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday.

Via Stocktwits

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since ↗

November 14, 2025

Via MarketBeat

Ozempic Maker Novo Nordisk Faces Board Shakeup ↗

November 14, 2025

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market.

Via Benzinga

Why Is Everyone Talking About Novo Nordisk Stock? ↗

November 14, 2025

There is hardly a dull moment for the drugmaker these days.

Via The Motley Fool

Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO ↗

November 14, 2025

The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.